FAST Launches A New Biotech To Find Cures For Angelman Syndrome

03/20/2018 Research

min. read

Topics

Neurological Research Institute

FAST Launches A New Biotech To Find Cures For Angelman Syndrome

The Foundation for Angelamn Syndrome Therapeutics (FAST) launches a new biotech, GeneTx Biotherapeutics LLC (GeneTx), a subsidiary of FAST, for the development and commercialization of an investigational antisense drug, GTX-101, for the treatment of Angelman syndrome (AS), a rare genetic disorder characterized by epilepsy, impaired motor function and speech delays. Read More